This study is recruiting. It focuses on schizophrenia and currently lists participation information in Portugal.
This study is looking at explore to what extent this intervention can be effectively implemented in countries with the characteristics of Portugal for people with psychosis, Schizophrenia, bipolarity, or Schizo Affective Disorder. Participants take part in a digital support tool and complete follow-up assessments. Some participants may receive Control instead of the study treatment, and direct benefit is not guaranteed.
The official record suggests in-person participation through a hospital, with sites including Centro Hospitalar Lisboa Ocidental in Lisbon, Centro Hospitalar Universitário Lisboa Norte in Lisbon, and Hospital Beatriz Ângelo in Loures. Participation appears to involve guided sessions or support activities with check-ins on how they fit into daily life. The main fit is usually matching the main diagnosis and having a stable enough treatment background for the study, while common reasons not to take part include safety concerns that need urgent care first and major medical issues that could make participation unsuitable. The official record does not list a formal phase, which usually means this is focused more on feasibility, delivery, or support than a standard drug-development stage.
This study may matter because it adds public evidence around schizophrenia. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordThis form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Taking part may help improve understanding of your condition.
It requires regular follow-up, often through questionnaires or interviews.
Requires travel, with in-person participation in Portugal.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
This study is exploring digital app or tool for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.
This study is sponsored by Lisbon Institute of Global Mental Health - LIGMH. Based on the sponsor name or official registry information, it appears to be a research institute. You should verify the details in the official registry record.
This study may involve digital app or tool, study visits, and assessments. The time commitment is multiple visits or assessments. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.